Jiudian Pharmaceutical announced that the 16th meeting of the fourth board of directors of the company reviewed a number of proposals. It was agreed to add “information technology consulting services” and “software development” to the scope of business, revise the “Articles of Association”, and submit them to the shareholders' meeting for review. Proposals to formulate and revise some governance systems are passed item by item, and most of them need to be submitted to the shareholders' meeting. Due to the resignation of former Audit Committee member Zhu Zhiyun, Lu Shang, the employee representative director, was by-elected as a member of the Audit Committee. It was agreed to sign a “Patent and Technology Transfer Agreement” with Suzhou Yuanju Pharmaceutical Technology. The transfer cost will not exceed 400 million yuan. Additionally, the 2025 Second Extraordinary General Meeting of Shareholders will be held on December 30.

Jiudian Pharmaceutical announced that the 16th meeting of the fourth board of directors of the company reviewed a number of proposals. It was agreed to add “information technology consulting services” and “software development” to the scope of business, revise the “Articles of Association”, and submit them to the shareholders' meeting for review. Proposals to formulate and revise some governance systems are passed item by item, and most of them need to be submitted to the shareholders' meeting. Due to the resignation of former Audit Committee member Zhu Zhiyun, Lu Shang, the employee representative director, was by-elected as a member of the Audit Committee. It was agreed to sign a “Patent and Technology Transfer Agreement” with Suzhou Yuanju Pharmaceutical Technology. The transfer cost will not exceed 400 million yuan. Additionally, the 2025 Second Extraordinary General Meeting of Shareholders will be held on December 30.